Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases.
de novo onset
deterioration
immunoglobulin A nephropathy
immunoglobulin A vasculitis
severe acute respiratory syndrome coronavirus 2 vaccination
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
revised:
02
12
2021
received:
08
11
2021
accepted:
17
01
2022
pubmed:
2
3
2022
medline:
6
5
2022
entrez:
1
3
2022
Statut:
ppublish
Résumé
Immunoglobulin (Ig)A vasculitis/nephropathy is a systemic immune complex-mediated vasculitis. Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is widely recommended in individuals without specific allergy to the vaccine components, it is arguable whether vaccination is advisable for patients with IgA vasculitis or for predisposed individuals. We and others have presented cases of IgA vasculitis occurring after SARS-CoV-2 vaccination. In total, these 19 cases, including ours, involved predominantly female patients, and half of them were suffering from de novo vasculitis onset. The most frequent manifestation was gross hematuria (89.5%) while skin lesions were relatively infrequent, occurring in only five cases (26.3%), of which three (15.8%) were confirmed to be IgA vasculitis. Taken together, these cases suggest that SARS-CoV-2 vaccination might be a trigger for development/deterioration of IgA vasculitis/nephropathy.
Identifiants
pubmed: 35229346
doi: 10.1111/1346-8138.16326
pmc: PMC9111130
doi:
Substances chimiques
COVID-19 Vaccines
0
Immunoglobulin A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
560-563Subventions
Organisme : grants from the Ministry of Education, Culture, Sports, Science and Technology
ID : 24390276
Organisme : Ministry of Health, Labor, and Welfare
Organisme : Ministry of Education, Culture, Sports, Science, and Technology
Informations de copyright
© 2022 Japanese Dermatological Association.
Références
Kidney Int. 2021 Aug;100(2):469-471
pubmed: 34033857
Kidney Int. 2021 Aug;100(2):466-468
pubmed: 34087252
Autoimmun Rev. 2021 Nov;20(11):102951
pubmed: 34509658
Lancet Rheumatol. 2021 Sep;3(9):e617
pubmed: 34250509
J Dermatol. 2022 May;49(5):560-563
pubmed: 35229346
Kidney Int. 2021 Jun;99(6):1487
pubmed: 33771584
Vaccines (Basel). 2021 May 27;9(6):
pubmed: 34072058
Kidney Int. 2021 Jul;100(1):238
pubmed: 33932458
J Taibah Univ Med Sci. 2022 Feb;17(1):1-13
pubmed: 34602936
Autoimmun Rev. 2021 Jan;20(1):102707
pubmed: 33197572
Vaccine. 2021 Jul 30;39(33):4571-4572
pubmed: 34247902
Kidney Int Rep. 2021 Aug;6(8):2246-2247
pubmed: 34179593
Kidney Int. 2021 Aug;100(2):468-469
pubmed: 34146600
Arthritis Rheumatol. 2021 Dec;73(12):2188
pubmed: 34196469
Ann Rheum Dis. 2010 May;69(5):798-806
pubmed: 20413568